MetaCap

Biomea Fusion (BMEA) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Biomea Fusion (BMEA) over the past year, losing 41.4% versus a loss of 41.5%. Over five years, TLPH leads with a -94.0% price change compared with -95.2% for BMEA. Biomea Fusion is the larger company by market cap ($41.7 million vs $40.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%TLPH-41.40%
+134%+37%-59%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%TLPH-94.55%
+298%+91%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus TLPH key metrics
MetricBMEATLPH
Share price$0.5744$0.7852
Market cap$41.75M$40.80M
1-day change-2.38%+6.25%
YTD return-53.68%-31.12%
1-year return-41.51%-41.40%
5-year return-95.21%-93.96%
EPS (TTM)$-0.10$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$28.00K
Net income (latest FY)$-61.80M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$2.24$1.57
52-week low$0.45$0.69
Distance from 52-week high-74.32%-49.99%
Analyst consensusbuynone
Avg. price target upside+1118.66%+298.62%
Average volume2.22M144.13K
Shares outstanding72.68M51.96M
Employees3712
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

BMEA vs TLPH FAQ

Which is bigger, Biomea Fusion or Talphera?

Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $40.80M for Talphera (TLPH).

Which stock has performed better over the past year, BMEA or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -41.51% for BMEA (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons